Skip to main content

Table 2 Summary of the clinical parameters of patients with rheumatoid arthritis

From: Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease

  Responders Non- or moderate responders Responders Non- or moderate responders  
  Test cohort Validation cohort Difference
At baseline 6 13 4 11  
Gender (male/female) 1/5 2/11 0/4 3/8  
Age (years) 44.3±9.3 47±10.7 54±17 56.2±6.8 Non-significant
DAS28 5.6±0.3 5.2±0.7 5.2±0.06 5.4±0.5 Non-significant
HAQ 1.2±0.7 2±0.6 1.5±1.1 1.9±0.7 Non-significant
CRP (mg/ml) 16.8±18.3 28.3±23.8 18.9±18.3 9.5±10.3 Non-significant
DMARDs 2.8±0.9 2.6±0.7 3±0.8 2.7±1.4 Non-significant
  1. CRP, C-reactive protein;DAS28, Disease Activity Score; HAQ, Health Assessment Questionnaire; DMARD, disease-modifying anti-rheumatic drug (methotrexate). Data are shown as mean±SD.